Sensorion SAS (FR:ALSEN)
:ALSEN
Want to see FR:ALSEN full AI Analyst Report?
Top Page
Sensorion SAS
(ALSEN)
Select Model
Select Model
Rating:46Neutral
Price Target:
€0.41
▲(2.50% Upside)
Action:ReiteratedDate:03/25/26
The score is primarily constrained by weak financial performance—large ongoing losses, heavy cash burn, and the 2025 revenue dropping to zero—despite relatively low leverage. Technical signals are mixed but tilt weak in the near term, and valuation is limited by a negative P/E with no dividend yield support.
Positive Factors
Low leverage
Modest historical debt limits fixed interest obligations and preserves balance-sheet flexibility, a durable advantage for a cash-burning clinical-stage biotech. Low leverage reduces refinancing risk, making it easier to fund trials or secure partnership deals without heavy interest drag.
Negative Factors
High cash burn
Sustained large operating outflows create ongoing funding needs and shorten the cash runway, forcing recurring external financing. Over 2–6 months this elevates dilution risk, constrains R&D pacing, and can pressure partner negotiations and long-term strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Modest historical debt limits fixed interest obligations and preserves balance-sheet flexibility, a durable advantage for a cash-burning clinical-stage biotech. Low leverage reduces refinancing risk, making it easier to fund trials or secure partnership deals without heavy interest drag.
Read all positive factors
Sensorion SAS (ALSEN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€204.09M
Dividend YieldN/A
Average Volume (3M)540.27K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue GrowthN/A
EPS Growth10.87%
CountryFR
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding514,946,960
10 Day Avg. Volume740,129
30 Day Avg. Volume540,266
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€18.88M
Sensorion SAS Business Overview & Revenue Model
Company Description
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otofer...
How the Company Makes Money
Sensorion does not appear to generate material recurring revenue from marketed products, as it is primarily a clinical-stage R&D company. Its cash inflows typically come from financing and partnering activities rather than product sales. Key ways ...
Sensorion SAS Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 6.65M | 5.70M | 4.93M | 4.26M |
| Gross Profit | -1.36M | 6.65M | 3.79M | 4.16M | 3.75M |
| EBITDA | -35.21M | -27.58M | -21.33M | -22.44M | -17.46M |
| Net Income | -29.43M | -25.97M | -22.06M | -23.21M | -15.14M |
Balance Sheet | |||||
| Total Assets | 57.89M | 89.28M | 46.50M | 38.93M | 59.02M |
| Cash, Cash Equivalents and Short-Term Investments | 47.46M | 76.98M | 36.97M | 26.20M | 50.00M |
| Total Debt | 1.23M | 2.20M | 2.87M | 3.76M | 3.99M |
| Total Liabilities | 13.41M | 17.14M | 13.23M | 17.06M | 15.03M |
| Stockholders Equity | 44.48M | 72.14M | 33.27M | 21.87M | 43.98M |
Cash Flow | |||||
| Free Cash Flow | -27.64M | -22.45M | -21.94M | -22.92M | -11.81M |
| Operating Cash Flow | -27.39M | -21.33M | -21.07M | -21.41M | -10.77M |
| Investing Cash Flow | 9.24M | -11.13M | -381.06K | -1.54M | -1.07M |
| Financing Cash Flow | -1.16M | 62.26M | 32.20M | -820.68K | -715.07K |
Sensorion SAS Technical Analysis
Positive
0.40
Price Trends
0.41
Negative
0.36
Positive
0.35
Positive
Market Momentum
-0.01
Positive
47.10
Neutral
41.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Positive. The current price of 0.4 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.41, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 41.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALSEN.
Sensorion SAS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | €257.19M | -7.03 | -30.75% | ― | 150.80% | 67.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €214.04M | -3.69 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €883.23M | -12.22 | ― | ― | 166.31% | 43.80% | |
46 Neutral | €204.09M | -3.44 | -40.00% | ― | ― | 10.87% | |
45 Neutral | €19.45M | -1.29 | 51.23% | ― | -92.35% | 63.25% |
* Healthcare Sector Average
FR:ALSEN
Sensorion SAS
0.40
0.23
135.88%
FR:ALCOX
Nicox SA
0.43
0.20
87.28%
FR:TNG
Transgene
0.77
0.16
26.39%
FR:SIGHT
GenSight Biologics SA
0.08
-0.15
-64.16%
FR:ALCLS
Cellectis SA
3.78
2.47
188.26%
FR:MEDCL
MedinCell SA
24.26
10.15
71.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.